Enlivex Therapeutics Ltd. (ENLV)
Chart Events
Performance Outlook
| Previous Close | 1.6100 |
| Open | 1.6000 |
| Bid | 1.4600 x 2200 |
| Ask | 1.6000 x 900 |
| Day's Range | 1.4503 - 1.6000 |
| 52 Week Range | 1.4503 - 4.9200 |
| Volume | |
| Avg. Volume | 23,998 |
| Market Cap | 27.154M |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2500 |
| Earnings Date | Dec 15, 2023 - Dec 19, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ENLV
Related Research
- Enlivex Therapeutics Ltd.Daily – Vickers Top Buyers & Sellers for 08/30/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat25 days agoArgus Research
GlobeNewswireEnlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Nes-Ziona, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the H.C. Wainwright 25th Annual Global Investment Conference, which will take place at the Lotte New York Palace Hotel in New York City, NY Sep 11-13. The presentation will take place on Sep 12, 2023, at 5:00 PM Eastern Time. A webcast of the presentation will be
- GlobeNewswire
Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19
Data published in Frontiers in Immunology show a robust safety profile and rapid resolution from ARDS and parallel resolution of inflammation markers and elevated cytokines/chemokines, as well as substantial improvements in mortality in 21 Allocetra-treated patients with COVID-19 vs. matched historical controls Nes-Ziona, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announ
- GlobeNewswire
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first patient has been dosed under the amended protocol for the Company’s Phase II trial evaluating Allocetra™ in patients with sepsis. As previously announced, the amended protocol allows a higher SOFA score inclusion range, which allows the recruitment of patients with higher levels of sepsis seve
